Literature DB >> 6770584

Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease.

T B Wahlberg, M Blombäck, I Overmark.   

Abstract

Forty-five patients with ischemic cerebrovascular disease (ICD) and 44 with deep venous thrombosis (DVT) and/or pulmonary embolism (PE) have been investigated in a non-active state of the disease with VIIIR:Ag, plasminogen activator before and after stasis, antiplasmin, antithrombin (activity, antigen, activity/antigen ratio) and spontaneous platelet aggregation. Control groups of 20 respectively 80 healthy females and males were used in the study. VIIR:Ag was elevated in the group with deep venous thromboembolic disease compared with the ICD group and a control group. VIIIR:Ag in the ICD group was elevated compared with the control group. Plasminogen activator determined before and after stasis was lowered in the two diseased groups. There was no statistically significant difference in any of the blood coagulation variables between patients on or off coumarol treatment. The patients on courmarol were, however, not reinvestigated when this medication had been withdrawn. Antithrombin levels below the reference interval of the control group of 80 blood donors were found in 11.4% of the patients with DVT/PE, whiel no patient in the ICD group had low antithrombin values.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6770584     DOI: 10.1111/j.0954-6820.1980.tb09743.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  6 in total

1.  Antithrombin III deficiency in ischaemic stroke.

Authors:  V Hossmann; W D Heiss; H Bewermeyer
Journal:  Klin Wochenschr       Date:  1983-06-15

2.  Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis.

Authors:  S Wållberg-Jonsson; G H Dahlén; T K Nilsson; M Rånby; S Rantapää-Dahlqvist
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

Review 3.  von Willebrand factor and its relevance to cardiovascular disorders.

Authors:  G Y Lip; A D Blann
Journal:  Br Heart J       Date:  1995-12

4.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.

Authors:  J H Jansson; T K Nilsson; O Johnson
Journal:  Br Heart J       Date:  1991-11

5.  The effect of intravenous tissue-type plasminogen activator in a rat model of embolic cerebral ischemia.

Authors:  P L Penar; C A Greer
Journal:  Yale J Biol Med       Date:  1987 May-Jun

6.  Thrombin Generating Capacity and Phenotypic Association in ABO Blood Groups.

Authors:  Romy M W Kremers; Abdulrahman B O Mohamed; Leonie Pelkmans; Salwa Hindawi; H Coenraad Hemker; H Bas de Laat; Dana Huskens; Raed Al Dieri
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.